Should I buy LivaNova (LIVN) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on LivaNova
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Baird | 67 % | +21.1 % | 6 | $76 +0% |
| Needham | 59 % | +12.5 % | 27 | $93 +22% |
| Stifel | 33 % | +8.1 % | 6 | $70 -8% |
| Goldman Sachs | 20 % | -1.4 % | 5 | $55 -28% |
| Mizuho | 33 % | -3.2 % | 6 | $95 +24% |
✅ Reasons to believe
- 86% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
- Median price target $92, i.e. +20% from the current price ($76).
⚠️ Reasons to hesitate
- Even the most reliable firm on LIVN, Baird (67% hit rate, 6 scored calls), only targets $76 (call made on May 7, 2026, maturing on May 7, 2027) (+0%) in its most recent call, and $63 (call made on November 6, 2025, maturing on November 6, 2026) (-18%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 7 ratings, 1 is neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on LIVN
Median target $92 (+20%) · 7 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in LivaNova now?
We won't decide for you. The facts: 86% of analysts rate it a buy, median target $92 (+20%), and Baird (most reliable on LIVN, 67%) targets $76. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in LivaNova?
Not according to analysts: the median target ($92) is still +20% above the current price ($76) (most reliable on LIVN: Baird, 67%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is LivaNova still worth investing in?
It depends on the gap between the price ($76) and its estimated value: analysts target $92 on median (+20%), with 86% buys (most reliable on LIVN: Baird, 67%). Cross-check with their real reliability on LIVN and the cautions above. Information, not advice.
What's the main risk in buying LIVN?
Even the most reliable firm on LIVN, Baird (67% hit rate, 6 scored calls), only targets $76 (call made on May 7, 2026, maturing on May 7, 2027) (+0%) in its most recent call, and $63 (call made on November 6, 2025, maturing on November 6, 2026) (-18%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full LivaNova profile (consensus, analyst reliability, price target, performance).